Evidence profile
Tirzepatide (50 mg Vial)
Tirzepatide has authorized manufactured products with specific indications and safety information. Clinical information should always name the product being discussed.
01
Product identity
Mounjaro, Mounjaro KwikPen and Zepbound are named manufactured products with defined formulations and indications; a powder vial requires its own identity and documentation.
The supplier heading reads “Tirzepatide | 50mg”, but a size field in its description says 10mg. The linked heading identifies this catalogue variant; the amount and formulation of supplied stock require confirmation before any quantity is used.[6]
02
What has been studied
Authorized-product monograph
Mounjaro in Canada
- Population or model
- Indication- and age-specific populations in the monograph
- Study route or material
- Manufactured subcutaneous injection solution
The June 2026 Mounjaro monograph provides the relevant formulation, diabetes-indication and safety context. Its instructions belong to the manufactured product described there.[1]
Authorized-product monograph / Regulatory product database
Zepbound is also authorized in Canada
- Population or model
- Adults meeting the labeled weight-management or obstructive-sleep-apnea criteria; Canadian product authorization
- Study route or material
- Manufactured subcutaneous solution in a multidose prefilled KwikPen; Subcutaneous solution in a multidose prefilled pen
The Canadian Zepbound monograph dated 11 June 2026 covers chronic weight management in eligible adults and moderate-to-severe obstructive sleep apnea in adults with obesity. It describes a manufactured solution in a multidose prefilled KwikPen. These indications and product instructions do not extend to a retail research powder vial.[2][3]
03
Evidence limits
The listed research vial is not established as equivalent to an authorized product.
There is no clinical sign-off for patient-facing instructions in this profile.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
DIN, named product and device or dosage form when discussing an authorized medicine.
Actual vial content, excipients and manufacturer-supported stability.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[5]
05
Approval context
Mounjaro and Zepbound have product-specific Canadian authorizations. Their indications and formulations differ; the linked research listing is not automatically covered.[1][2][3]
06
Sources and review scope
- Mounjaro Canadian product monographAuthorized-product monograph · Fresh official monograph: cover/formulation and indication passages; selected safety context carried forward · Checked 2026-09-09
- Zepbound Canadian product monographAuthorized-product monograph · Fresh official monograph: cover/formulation and indication passages; selected safety context carried forward · Checked 2026-09-09
- Health Canada Drug Product Database: ZepboundRegulatory product database · Current Health Canada product record · Checked 2026-09-08
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: Tirzepatide | 50mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.